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Retromer stabilization results in neuroprotection
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Amyotrophic Lateral Sclerosis (ALS) is a fatal disease characterized by the degeneration of
upper and lower motor neurons (MNs). We find a significant reduction of the retromer
complex subunit VPS35 in iPSCs-derived MNs from ALS patients, in MNs from ALS post
mortem explants and in MNs from SOD1G93A mice. Being the retromer involved in traf-
ficking of hydrolases, a pathological hallmark in ALS, we design, synthesize and characterize
an array of retromer stabilizers based on bis-guanylhydrazones connected by a 1,3-phenyl
ring linker. We select compound 2a as a potent and bioavailable interactor of VPS35-VPS29.
Indeed, while increasing retromer stability in ALS mice, compound 2a attenuates locomotion
impairment and increases MNs survival. Moreover, compound 2a increases VPS35 in iPSCs-
derived MNs and shows brain bioavailability. Our results clearly suggest the retromer as a
valuable druggable target in ALS.
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Amyotrophic Lateral Sclerosis (ALS) is a devastating dis-order, featured by a progressive degeneration of brain andspinal cord (SC) motor neurons (MNs). Clinical outcomes
involve muscle weakness, movement defects, speech disturbances,
dysphasia, and eventually death by respiratory failure1. The
pathobiology of ALS is not completely understood, although the
presence of cytoplasmic inclusions of protein aggregates in neu-
rons is a key hallmark of ALS pathophysiology2.
Most ALS patients (90%) are sporadic, while only ≈10% display
a positive family history (fALS). Around 20% of fALS patients
show mutations in the copper/zinc superoxide dismutase (SOD1)
gene3. The ALS-linked G93A mutation of SOD1 allowed the
establishment of a mouse model, featuring MN degeneration in
the SC4. Mutant SOD1 proteins misfold, filling MNs with toxic
aggregates, which impinge on their survival5. Unlike proliferating
cells, which dilute aggregated proteins at each round of cell
division, neurons degrade these aggregates only through the
ubiquitin-proteasome system, or the autophagy-lysosomal
pathway6.
Lysosomal health is crucial for the degradation of dysfunctional
proteins and in particular for the clearance of autophagic
vacuoles. An impaired lysosomal system contributes to autophagy
stress, accumulation of damaged mitochondria, and restricts
clearance of proteins aggregates. Remarkably, lysosome impair-
ment is among the earliest pathological events that affect MNs in
G93A mice7.
Delivery of proteolytic enzymes to lysosomes needs the coor-
dinated action of multiple protein regulators, among which the
highly conserved retromer complex8. The retromer complex was
initially described for its ability to sort plasma membrane proteins
from endosomes to the trans-Golgi network, or back to the cell
surface. Two subcomplexes assemble in the cytoplasm to produce
the retromer complex. The former is a trimeric complex com-
posed by vacuolar protein sorting (VPS) 35, 29, and 26 that
assemble into the cargo recognition core (CRC) complex9. The
latter consists of sorting-nexin (SNX) proteins, either containing
phox-homology (PX) and bin/amphiphysin/rvs (BAR) domains,
or only the former one10–13. The retromer recycles specific car-
gos, such as Vps10/Sortilin protein family members14 or the
cation-independent mannose 6-phosphate receptor (CI-MPR)15.
The latter is involved in the delivery of proteolytic enzymes to
lysosomes. A point mutation in VPS35 (D620N) is causative of an
autosomal dominant form of Parkinson’s disease (PD)16,17 and
affects early steps of autophagosome formation18. VPS35 defi-
ciency alters the distribution of lysosome-associated membrane
glycoprotein 2a (Lamp2a) in neurons19.
Pharmacological tools, increasing the interaction between
members of the CRC complex, increase retromer stability and
enhance retromer-mediated trafficking of cargos. The isothiourea
chaperone R55/1 stabilizes the VPS35-VPS29 interaction,
increases retromer levels in vitro, and decreases pathogenic pro-
cessing of APP in cells20.
We describe a substantial reduction of CRC proteins in MNs of
G93A mice; a similar VPS35 downregulation in SCs from ALS
patients and in inducible pluripotent stem cells (iPSCs)-derived
MNs. We design, synthetize and characterize a small array of bis-
guanylhydrazones. Such retromer stabilizers possess good in vivo
bioavailability, potency, and stability. We selected phenyl-1,3-bis-
guanylhydrazone 2a for extended in vitro and in vivo char-
acterization in ALS models.
Results
CRC proteins are downregulated in G93A mice. A loss of
Cathepsin D (CSTD) along with endo-lysosomal deficits affects
MNs of G93A mice7. As these alterations could implicate
retromer functionality21, we studied CRC proteins in SCs from
G93A mice. VPS35 immunoreactivity in cultured neurons is
organized in puncta that localize throughout the cell soma,
dendrites, and axons9,22,23. Accordingly, immunofluorescence
(IF) analysis of VPS35+ puncta showed their clustering in the
soma and cytoplasmic bundles of ventral horn wild-type (WT)
MNs (Fig. 1a and Supplementary Fig. 1a). VPS35 immunor-
eactivity was substantially attenuated in MNs of asymptomatic
and symptomatic G93A mice (Fig. 1a and Supplementary Fig. 1b,
c). Similarly, we observed attenuated VPS26 immunoreactivity in
parallel SC sections (Fig. 1b and Supplementary Fig. 1d–f). We
next assayed the levels of VPS35, VPS29, and the VPS26b isoform
highly expressed in the CNS24 by western blotting lumbar SC
extracts from G93A mice. We observed a significant reduction of
VPS35 in asymptomatic and symptomatic G93A mice, as well as
a reduction of VPS26b and VPS29 in symptomatic G93A mice
(Fig. 1c–e and Supplementary Fig. 1g, h). These results confirm
that a loss of any of the CRC components leads to instability and
rapid degradation of the remaining proteins25. Conversely, we did
not find alterations of VPS35 and VPS26 immunoreactivities in
NeuN+ cells sampled in the motor cortex of G93A mice (Sup-
plementary Fig. 2a–f). We next assayed Vps35, Vps26, and Vps29
mRNAs levels in lumbar SC extracts by real-time PCR. Despite
the reduction of VPS protein levels, their mRNA levels did not
drop significantly when compared with WT controls, suggesting
that their reduction was not caused by transcriptional inhibition
(Fig. 1f).
Design and synthesis of new pharmacological chaperones. R55/
1 binds to a characterized hot spot at the interface between VPS35
and VPS2920. We replaced the 2,5-disubstituted thiophene scaf-
fold in R55/1 with a phenyl ring. Phenyl and thiophene rings are
bio-isosters26, and the former offers more synthetic versatility,
i.e., can be substituted for structure activity relationship (SAR)
acquisition. We substituted isothioureas with guanylhydrazones,
as the latter groups show good stability and a pKa range closer to
neutrality due to the delocalization of their charge on three N
atoms (favored azine form vs. disfavored hydrazone form, 4.5 ≤
ΔGT ≤ 6.5 Kcal/mol27, Supplementary Fig. 3). The pKa range of
guanylhydrazones should ensure a higher permeability through
lipophilic bio-membranes, due to an estimated ≈16% free base at
37 °C and pH= 7.428. Their presence in drugs29 endowed with
blood-brain barrier (BBB) permeability30 supports our choice.
Six compounds were then studied in silico for their putative
affinity for the retromer complex. Standard thiophene bis-
isothiourea R55/120, and compounds bearing one (3a–5a) or
both described modifications (2a, 6a) (Fig. 2a) were studied in
silico for their putative affinity for the retromer complex. Their
docking site was set at the interface between VPS35 and VPS29
(PDB code: 2R17), where R55/1 binding was revealed by point
mutation20. We determined the interaction energy between each
compound (best pose) and the VPS35-VPS29 interface (calcu-
lated Kd). A normalized Kd took into account its recurrence in
40 simulation runs using a sigmoid function/multiplication factor
(MF), varying between 2 (lowest recurrence, i.e., 1 in 40 poses)
and 0.1 (highest recurrence, i.e., 40 in 40 poses). The function is
neutral (MF= 1) for a 50% recurrence (20 in 40 poses), and
favors/penalizes compounds with high/low recurrent poses
(Supplementary Fig. 4a). Figure 2b lists calculated and normal-
ized Kd values for standard R55/1 and compounds 2a–6a, which
show limited differences. We docked R55/1 (orange yellow in
Fig. 2c), obtaining a calculated Kd= 128.5 µM and a normalized
Kd= 189.0 µM (15/40 poses). Its best docking pose suggested a
thiophene–benzene ring replacement filling a small surface recess
surrounded by the Phe541 residue in VPS35, and by Tyr139 and
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Thr144 residues in VPS29 (surface recess 1, Fig. 2c). Therefore,
we modelled either a 1,3-(meta, compound 4a, yellow in Fig. 2d)
or a 1,4-phenyl bis-isothiourea (para, compound 5a, light blue in
Fig. 2d). In silico docking suggested that meta-substitution should
preserve the favorable geometry of R55/1, slightly improving the
interaction with surface recess 1 (calculated Kd= 82.1 µM for 4a)
with good recurrence (normalized Kd= 27.5 µM-29/40 poses).
Para substitution showed a reduced interaction (calculated Kd=
290.6 µM) with low recurrence (normalized Kd= 561 µM-7/40
poses) through repositioning of an isothiourea group in 5a
toward another surface cavity (surface recess 2, Fig. 2d), and the
loss of electrostatic interactions with Glu545. We then replaced
isothioureas with two meta-guanylhydrazones (compound 3a,
violet in Fig. 2e), showing a pose similar to R55/1, with improved
affinity (calculated Kd= 9.2 µM) and good recurrence (normal-
ized Kd= 5.1 µM-25/40 poses). When phenyl and 1,3 guanylhy-
drazones were introduced in compound 2a (gray in Fig. 2e and
Supplementary Fig. 4b, e–g), it displayed a favorable orientation
with the phenyl ring filling surface recess 1, further increasing
affinity for the putative binding site (calculated Kd= 1.8 µM)
with high recurrence (normalized Kd= 0.53 µM-35/40 poses).
The good interaction of phenyl-1,4 guanylhydrazone (compound
6a, calculated Kd= 3.8 µM) was penalized by its low recurrence
(normalized Kd= 7.1 µM-9/40 poses).
The predicted partition coefficient (logP—bioavailability) and
pKa values (neutral/charged ratio at physiological pH) were
calculated for compounds 2a–6a, and standard R55/1. LogP
values around 2.1 were suggested for isothioureas 1, 4a, and 5a,
while values around 0 were suggested for guanylhydrazones 2a,
3a, and 6a. Both values are aligned with Lipinski rules31,
supporting bioavailability for both compound families. Conver-
sely, predicted pKa values were lower for guanylhydrazones 2a,
3a, and 6a (pKa1 ≈ 7.5, pKa2 ≈ 8.1) than for isothioureas 1, 4a,
and 5a (pKa1 ≈ 10.2, pKa2 ≈ 10.8), suggesting a higher abundance
of neutral, BBB-permeable guanylhydrazones at physiological pH.
We synthesized compounds 2a–6a through short, high-
yielding strategies: isothioureas 4a and 5a from dichloromethyl-
benzenes and isothiourea (Supplementary Fig. 4c); phenyl
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Fig. 1 CRC proteins are downregulated in G93A MNs. a Maximal projections of confocal stacks of VPS35+NeuN+ putative MNs in the ventral horn of
lumbar SCs fromWT and G93A mice (30, 60 and 90 days, n= 4 biologically independent mice/time point). Adjacent sections labelled for VPS26 and NeuN
are shown in b, (30, 60 and 90 days, n= 4 biologically independent mice/time point). cWBs for VPS35 and β-Actin in lumbar SCs protein extracts fromWT
and G93A mice at 20, 60, and 100 days (n= 4 biologically independent mice/time point). The histogram shows quantifications (mean ± SD) of normalized
VPS35 levels (ratio versus WT), (WT vs. G93A day20: p= 0.007; day 60: p= 0.0015; day 90: p < 0.0001). d Representative WB for VPS26b and β-Tubulin
in SCs from WT and G93A mice at day 100. The histogram shows the quantification (mean ± SD) of normalized VPS26b levels (ratio versus WT, n= 5
biologically independent WT mice and n= 6 biologically independent G93A mice, p= 0.002). e Representative WB for VPS29 levels in SCs from WT and
G93A mice at day 100. The histogram shows the quantification (mean ± SD) of normalized VPS29 levels (ratio versus WT, n= 6 biologically independent
mice/group, p= 0.0019). f quantification of Vps35, Vps26, and Vps29 mRNAs by real-time PCR (ratio versus WT) in lumbar SCs from WT (sampled at day
60, n= 4 biologically independent mice) and G93A mice (30, 60, and 90 days, n= 3 biologically independent mice/time point). Two-way ANOVA followed
by Bonferroni multiple comparisons test was used to analyze data of c. Two-tailed Student’s t-test was used to determine the statistical significance in d and
e. One-way ANOVA followed by Tukey's Multiple Comparison test was used to analyze data of f. **p < 0.01; ***p < 0.001. Scale bar 80 µm.
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guanylhydrazones 2a, 3a, and 6a from aryl dialdehydes and
aminoguanidine (Supplementary Fig. 4d). We incubated Neuro2a
cells with compounds 2a–6a (10 µM) or with standard R55/1 (10
µM) for 48 h. Protein extracts were collected, separated by SDS-
PAGE and immunoblotted for VPS35 and the housekeeping gene
β-Actin. We observed limited cytotoxicity in cells receiving
compound 6a that prevented the measurement of their VPS35
levels. As expected, VPS35 levels increased in R55/1-treated
cells20. Similarly, compounds 2a, 3a, and 4a increased VPS35
levels, while compound 5a did not (Fig. 2f). Compound 2a
displays the lowest Kd value among molecules 2a–6a, and we
checked whether it could increase VPS26b and VPS29 levels.
Accordingly, VPS26b and VPS29 proteins were significantly
increased by compound 2a in Neuro2a cells after treatment for
48 h (Supplementary Fig. 5a).
In vivo delivery of compound 2a to the brain. Compounds 2a,
4a, and standard R55/1 (10 mg/Kg) were intraperitoneally injec-
ted in C57BL6J mice daily. After 1 week, mice were sacrificed,
saline perfused to avoid CNS contamination by compounds in
blood circulation, and SC protein extracts were assayed by WB.
While treatment with isothiourea 4a slightly, but not significantly,
increased VPS35 levels, phenyl-1,3-guanylhydrazone 2a sig-
nificantly increased VPS35 levels in SC extracts (Fig. 2g). Phar-
macokinetic analysis of C57BL6J brains receiving daily
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Fig. 2 Structure and binding modes for R55/1 and compounds 2a–6a. a Standard R55/1, compounds bearing one (3a–5a) or two modifications (2a, 6a), b
Calculated and normalized Kd values for compounds 2a–6a. c R55/1 (orange carbons atoms) positioned near a small cavity (surface recess 1) outlined by
Tyr139 and Thr144 in VPS29, and Phe541 in VPS35. d 1,3-meta substituted 4a (yellow carbon atoms) better fits into surface recess 1; 1,4-meta substituted
5a (cyan carbon atoms) repositions an isothiourea group in surface recess 2, with a predicted loss of affinity. e docking poses of 1,3-phenyl bis-isothiourea
3a (violet carbon atoms) and 1,3-phenyl bis-guanylhydrazone 2a (grey carbon atoms) in their putative binding site. f representative WB for VPS35 and β-
Actin in treated Neuro2a cells (10 μM, 48 h, 3 × 105 cells/well). Dividing black lines mark lanes cropped from the same filter. The histogram shows
quantifications (control: n= 11 independent wells; R55/1: n= 9 independent wells; 2a: n= 5 independent wells; 3a: n= 4 independent wells; 4a: n= 6
independent wells; 5a: n= 4 independent wells; 6a: n= 4 independent wells). Control vs. R55/1: p= 0.036, control vs. 2a: p < 0.0001, control vs. 3a: p=
0.048, control vs. 4a: p < 0.0001. g representative WB for VPS35 and β-Actin in SCs extracts from vehicle-, R55/1-, 2a- and 4a-treated (10 mg/kg for
7 days) C57BL/6J mice. Dividing black lines mark lanes cropped from parallel filters. The histogram shows quantifications (mean ratio ± SD, vehicle: n= 7
independent mice; R55/1: n= 5 independent mice; 2a: n= 8 independent mice; 4a: n= 7 independent mice. Vehicle vs. 2a p < 0.0001, R55/1 vs. 2a p=
0.002, 2a vs.4a p= 0.0012). h Brain uptake of compound 2a in C57BL/6J mice injected (10 mg/kg) with 2a (1, 7, 15, and 30 days, n= 4 independent
mice/time point, mean ± SD, p < 0.0001). i–l STD-NMR (i, k) and WL (j, l) spectra of 2a (500 μM). Spectra (i) and (j) are in presence of VPS29-VPS35
complex (10 μM), spectra (k) and (l) are controls. Stars indicate the proton resonances of the buffer.m Neuro2a cell viability (mean ± SD, reported as ratio
versus controls) in presence of increasing amounts of 2a (1–1000 µM, 48 h, 4 × 104 cells/well, n= 24 independent wells/group, three experiments).
Nonlinear fitting shows an LD50 of 257.9 µM. Controls were established by H2O2 treatment (200 µM for 48 h, n= 24 independent wells/group, untreated
vs. H2O2: p < 0.0001). One-way ANOVA followed by Tukey's Multiple Comparison test was used to analyze f, g, and h plots. Two-tailed Student’s t-test
was used to analyze data from m. *p < 0.05, **p < 0.01, ***p < 0.001.
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intraperitoneal injections of compound 2a confirmed its access to
the CNS (Fig. 2h). Therefore, phenyl-1,3-bis-guanylhydrazone 2a
was selected as an early lead.
NMR studies. We used a ligand-based NMR approach to localize
the binding between compound 2a and the VPS29-VPS35 het-
erodimer. These techniques provide binding information without
requiring any isotopic labeling of the proteins. Particularly,
Saturation Transfer Difference NMR (STD-NMR)32 and
WaterLogsy-NMR (WL-NMR)33 experiments were acquired in
buffer solutions containing a large excess of compound 2a
(500μM) with respect to VPS29-VPS35 (10 μM). Both STD-NMR
and WL-NMR focus on the NMR signals of the ligand and utilize
the magnetization transfer by the Nuclear Overhauser Effect
(NOE) between protein and ligand. STD-NMR experiments are
carried out by subtraction of a 1D 1H spectrum where the protein
protons are selectively irradiated (on-resonance spectrum) from a
spectrum in which the protein is not saturated (off-resonance
spectrum). The resulting STD spectrum only shows ligand proton
signals in contact with the macromolecule. The STD-NMR
spectrum (Fig. 2i) shows the aromatic signals of compound 2a in
presence of the VPS29-VPS35 heterodimer, strongly indicating an
interaction between the ligand and the protein complex.
WL-NMR entails magnetization transfer to the ligand from
either bulk water via a macromolecule, and/or the exchangeable
protons and the water molecules present in the binding site.
Positive peaks for proton resonances of the ligand in the WL-
NMR spectrum are observed for binders in presence of the
protein. Otherwise, negative peaks will indicate that a putative
ligand does not interact with the macromolecule. In the WL-
NMR spectrum (Fig. 2j) the aromatic signals of compound 2a in
presence of the VPS29-VPS35 heterodimer show positive peaks,
while proton resonances of the buffer (highlighted with stars in
Fig. 2j, l) show a negative phase, indicating that 2a binds to the
protein complex. As negative control, STD-NMR and WL-NMR
experiments were performed for compound 2a in absence of the
heterodimer. The absence of proton signals in the aromatic zone
and the presence of negative signals in STD-NMR (Fig. 2k) and
WL-NMR (Fig. 2l) spectra, respectively, confirms the binding
between compound 2a and the VPS29-VPS35 heterodimer.
Unfortunately, STD- and WL-NMR competition experiments
between 2a and R55/1 could not be performed since the latter
compound was not stable in our experimental conditions.
Compound 2a increases VPS35 levels. We next measured VPS35
degradation rates by a cycloheximide (CHX) chase assay. Neu-
ro2a cells received vehicle or compound 2a (10 µM) for 24 h, then
CHX was added and VPS35 levels were measured by WB. As
reported34, we observed that vehicle-treated cells exhibited a drop
of VPS35 levels (∼40%) after 8 h of CHX treatment. Conversely,
pretreating cells with compound 2a protected VPS35 from
degradation (Supplementary Fig. 6a, b).
Compound 2a, as R55/120, did not influence the transcription
levels of CRC genes in Neuro2a cells, as determined by measuring
Vps35, Vps26, and Vps29 mRNAs levels by real-time PCR
(Supplementary Fig. 6c).
We assessed the cytotoxicity of compound 2a, measuring
survival of Neuro2a cells exposed to increasing 2a concentrations.
The calculated LD50 was ∼260 µM (Fig. 2m), a higher value than
the concentration needed to stabilize the retromer in vitro. We
next checked for toxic effects of compound 2a in primary
neuronal cultures coupled with Micro Electrode Array (MEA)
devices. Mouse cortical neurons (E16.5) were plated on MEAs,
kept in culture for 14 days to develop firing activity and recorded
in presence of 2a. Low concentrations of compound 2a did not
alter neuronal firing, while we observed a slight reduction of
spikes only when neurons were incubated with 100 μM of 2a
(Supplementary Fig. 7a–c). These results indicate a wide
therapeutic window for compound 2a, considering the low μM
concentration needed in vitro to increase VPS35 levels.
Compound 2a counteracts SOD1G93A-mediated cytotoxicity.
The Golgi apparatus is affected in MNs from ALS patients and in
cells overexpressing mutant SOD1 forms35–37. We transiently
transfected Neuro2a cells with plasmids encoding SOD1G93A
before treatment with compound 2a. Confocal analysis of cells
labelled for trans-Golgi network marker Golgin97 revealed that
many SOD1G93A+ cells displayed trans-Golgi fragmentation.
Compound 2a significantly reverted this phenotype (Fig. 3a). We
next determined the viability of Neuro2a cells transfected with
SOD1G93A and exposed to compound 2a using a colorimetric
assay. Controls cells received LacZ plasmids. Compound 2a (10
μM, 48 h) did not affect cell survival (Fig. 2l and Fig. 3b). We
observed a slight, but not significant, reduction of cell viability in
LacZ-transfected Neuro2a cells (Fig. 3b). When SOD1G93A was
overexpressed, cell viability was greatly reduced. Notably, cell
viability was restored in SOD1G93A-transfected and compound
2a-treated Neuro2a cells (Fig. 3b). The increased cell viability
provided by compound 2a could result from unknown, non-
specific off-target effects. Therefore, we used plasmids encoding
VPS35 to increase/stabilize the retromer complex. Overexpression
of VPS35 did not affect Neuro2a cell viability, while SOD1G93A
greatly affected their survival (Fig. 3c). However, this phenotype
was reverted co-transfecting VPS35 and SOD1G93A plasmids
(Fig. 3c).
Having observed a marked improvement of viability in
SOD1G93A-transfected Neuro2a cells with VPS35 gain of function,
we investigated the effect of VPS35 loss of function. We
transfected Neuro2a cells with RNAi plasmids encoding a siRNA
duplex for VPS35, to knockdown VPS35 and disrupt the retromer
assembly38. The Sh56 plasmid significantly reduced VPS35
protein and mRNA levels and VPS35 immunoreactivity in cells,
when compared with a scramble plasmid (Supplementary
Fig. 8a–e). Downregulation of VPS35 by Sh56-encoding plasmids
did not affect Neuro2a cell survival (Fig. 3d). As previously
shown, cells receiving SOD1G93A plasmids displayed a significant
reduction of cell viability. By including Sh56 plasmids in the
transfection mix, we worsened this phenotype (Fig. 3d). Notably,
incubation of SOD1G93A-Sh56 double transfected cells with
compound 2a modestly increased cell viability, confirming that
compound 2a counteracts SOD1G93A-mediated cytotoxicity by
increasing VPS35 levels and retromer functionality. We next
assayed cytotoxicity by measuring lactate dehydrogenase (LDH)
release with a LDH-Glo™ cytotoxicity assay. Cells were treated
with plasmids encoding SOD1G93A and the Sh56-RNAi sequence
with or without compound 2a, while supernatants were used to
measure LDH contents. Overexpression of SOD1G93A increased
LDH release by Neuro2aA cells, when compared with control
cells (Fig. 3e). Compound 2a significantly reduced LDH release in
cells transfected with SOD1G93A, while LDH increased when cells
received SOD1G93A and Sh56 plasmids. Interestingly, high LDH
release was observed in Neuro2a cells transfected with SOD1G93A
and Sh56 plasmids and treated with compound 2a, further
confirming that 2a counteracts SOD1G93A-mediated cytotoxicity
by targeting the retromer (Fig. 3e).
Compound 2a ameliorates the phenotype of G93A mice. We
administered compound 2a (10 mg/kg, i.p.) daily to G93A and
WT littermates between day 30 and day 100. We observed a
slight, but not significant reduction of body weight in both WT
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and G93A mice (Fig. 4a). We did not observe alterations of
locomotion performances in WT mice treated with compound 2a
(Fig. 4b). We also did not observe distress or undesirable pain.
Strikingly, the progression of motor deficits in G93A mice was
significantly slowed down by compound 2a (Fig. 4c). Histo-
pathological analysis of lumbar SCs showed more MNs in ventral
horns of SCs from compound 2a-treated G93A mice than from
vehicle-treated G93A mice (Fig. 4d, e). We next assessed the
pathological degeneration of fibers in sciatic nerves of G93A mice
treated with compound 2a. We observed axonal degeneration,
with a substantial reduction of myelinated nerve fibers in vehicle-
treated G93A mice (Fig. 5a, b)39. Conversely, mice treated with
compound 2a showed a ∼30% reduction of degenerating fibers
(Fig. 5c, d). Using Luxol Fast Blue (LFB) to label lipoproteins of
the myelin sheath40, we analyzed myelination. Compound 2a-
treated G93A mice displayed a substantial reduction of
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Fig. 3 Compound 2a counteracts G93A-mediated Golgi fragmentation. a merged confocal stacks for GFP and Golgin97 in untransfected-; pcDNA3.1(+)
SOD1G93A (1 µg/well)-pCAAG-GFP (0.2 µg/well)-; pcDNA3.1(+)SOD1G93A (1 µg/well)-pCAAG-GFP (0.2 µg/well) + 2a (10 µM)- and pCAAG-GFP (1.2
µg/well)-transfected Neuro2a (4 × 104 cells/well). Morphological analysis of Golgi in normal, intermediate or fragmented was done in nontransfected cells
(n= 83 independent cells), G93A-GFP (n= 88 independent cells), G93A-GFP+ 2a (n= 84 independent cells), and GFP (n= 109 independent cells). The
histogram in panel a shows Golgi subclasses (% of the total number of Golgi constructs, means ± SD) examined over four independent experiments, p <
0.0001 for all comparisons. Protein lysates from nontransfected and transfected Neuro2a cells (3 × 105 cells/well, pcDNA3.1(+)SOD1G93A (2 µg/well)-
pCAAG-GFP (0.5 µg/well) or with pCAAG-GFP (2 µg/well) were immunoblotted with antibodies against Golgin97 and β-Actin. The histogram shows
quantifications (mean fold changes ± SD versus untreated cells, n= 3 wells/group). b Neuro2a cell viabilities (mean ratio ± SD compared to untransfected
cells, n= 19 independent wells) upon the following treatments: pCMV-LacZ (1.25µg/well, n= 18 independent wells), pcDNA3.1(+)SOD1G93A (1.25 µg/
well, n= 18 independent wells), pcDNA3.1(+)SOD1G93A (1.25 µg/well) + 2a (10 µM, n= 24 independent wells), and 2a (10 µM, n= 18 independent wells),
(4 × 104cells/well). Controls were obtained treating Neuro2A cells with H2O2 (200 µM, n= 16 independent wells). Data are examined over three
independent experiments (LacZ vs. G93A+2a p > 0.99; p < 0.0001 for the other comparisons). c Neuro2a cell viabilities (mean ratio ± SD versus untreated
cells) upon the following treatments: pCMV-LacZ+pcCDNA3.1-VPS35 (1 µg/well + 0.25 µg/well); pcDNA3.1(+)SOD1G93A+pCMV-LacZ (1 µg/well +
0.25 µg/well) and pcDNA3.1(+)SOD1G93A+pcCDNA3.1(+)VPS35 (1 µg/well + 0.25 µg/well), (4 × 104 cells/well); n= 17 biologically independent wells/
group examined over three independent experiments (p < 0.0001 for all comparisons). d Neuro2a cell viabilities (mean ratio ± SD versus untreated
Neuro2a, 4 × 104 cells/well, n= 18 independent wells) upon the following treatments: pCMV-LacZ (1 µg/well, n= 18 independent wells) with scramble or
with Sh56 plasmids (0.25 µg/well each, n= 18 independent wells); pcDNA3.1(+)SOD1G93A (1 µg/well) with scramble (n= 18 independent wells) or with
Sh56 plasmids (0.25 µg/well, n= 23 independent wells) and with or without compound 2a (10 µM, n= 18 independent wells); data are examined over
three independent experiments (Untrans. vs LacZ+scramble p= 0.72, Untrans. vs. LacZ+Sh56 p= 0.99, G93A+Sh56 vs. G93A+Sh56+2a p= 0.036, p <
0.0001 for the other comparisons). e LDH assay in Neuro2a (4 × 104 cells/well) receiving treatments and conditions as in panel d. Cytotoxicity (mean % ±
SD) was calculated by measuring amounts of LDH released in the supernatant (Untransf.: n= 12 independent wells, LacZ+scramble and LacZ+Sh56: n=
15 independent wells; G93A+scramble: n= 14 independent wells; G93A+Sh56: n= 16 independent wells; G93A+scramble+2a: n= 36 independent wells;
G93A+Sh56+2a: n= 23 independent wells, H2O2: n= 9 independent wells); data are examined over three independent experiments (Untrans. vs LacZ
+scramble p= 0.99, Untrans. vs. LacZ+Sh56 p= 0.98 G93A+scramble vs. G93A+Sh56+2a p= 0.73, p < 0.0001 for the other comparisons). Two-way
ANOVA followed by Bonferroni multiple comparisons test was used to analyze data of panel a. One-way ANOVA followed by Tukey's Multiple
Comparison test was used to analyze data of b–e. *p < 0.05, ***p < 0.001, n.s. not significant. Scale bar in a, 10 µm.
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demyelination when compared with vehicle-treated G93A mice
(Supplementary Fig. 9a–d). Parallel sections, labelled for myelin
basic protein (MBP) and medium neurofilaments (NF-M),
showed deranged myelin in vehicle-treated G93A mice while
compound 2a treatment preserved the integrity of myelin in
G93A mice (Supplementary Fig. 9e).
Cell-secreted SOD1G93A in the extracellular space activates
microglia by interaction with CD1441,42. Therefore, we analyzed
microglia/macrophages in SCs scoring Iba1+ cells and measured
CD14 expression levels in G93A mice. Neither CD14 levels nor
the total number of Iba1+ cells changed in compound 2a-treated
G93A mice when compared with vehicle-treated mice (Supple-
mentary Fig. 10a–c). Our finding supports earlier reports of a
rescue of behavioral deficits and pathological outcomes in 3XTg
AD mice treated with an AAV-VPS35 vector, without functional
alterations of the microglia/macrophage cell population43,44.
Compound 2a increases VPS35/VPS26 levels in G93A mice.
Standard R55/1 increases VPS35 and VPS26 levels, and retromer
functionality in cultured cells20. We asked whether compound 2a
could do the same in G93A MNs, using confocal microscopy to
quantify VPS35 fluorescence levels in MNs gated in the ventral
horn of lumbar SCs. We observed a significant reduction of
VPS35 mean fluorescence intensity (MFI) levels in vehicle-treated
G93A mice. In contrast, treatment with compound 2a sig-
nificantly increased such levels in MNs of G93A mice (Fig. 6a).
We next assayed VPS26 MFI levels on parallel sections. As
expected, MFI levels were reduced in vehicle-treated G93A mice,
while they were significantly increased in compound 2a-treated
mice (Fig. 6b). WBs of lumbar SC extracts confirmed the ability of
2a to increase VPS35 and VPS26b levels in G93A mice (Sup-
plementary Fig. 11a, b).
We next asked whether increasing VPS35/26 protein levels is
sufficient to increase retromer functionality. CI-MPR is unstable
in VPS26-knockout cells21, and we observed a substantial
reduction of CI-MPR MFI levels in MNs of vehicle-treated
G93A mice compared with WT litters (Fig. 6c). However, MFI
levels significantly increased in compound 2a-treated G93A MNs
(Fig. 6c). Sortilin encodes a receptor belonging to the Vps10
family involved in Frontotemporal Dementia (FTD)45, which
shares functional homologies with MPRs and is another retromer
cargo46. Sortilin MFI levels were significantly reduced in MNs of
vehicle-treated G93A mice, while significantly increased by
compound 2a (Fig. 6d).
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We next investigated Cathepsin D (CTSD) expression and
distribution in G93A mice, since its trafficking involves the
retromer complex21. In humans, CTSD maturation starts with a
pre-pro-CTSD then converted to pro-CTSD (52 kDa) in the
endoplasmic reticulum. Recycling of pro-CTSD and its down-
stream migration to acidic compartments involves CI-MPR and
the retromer pathway21. Pro-CTSD is further processed to an
intermediate form in late endosomes (48 kDa), and finally
converted to mature CTSD (34 kDa) in lysosomes47. VPS35
inactivation48 or VPS26 knockdown21 affect CTSD maturation.
We scored CTSD levels in lumbar SC extracts from vehicle-
treated WT and vehicle- or 2a-treated G93A mice. We observed a
slight, but not significant reduction of the mature CTSD/pro-
CTSD ratio in SC extracts of vehicle-treated G93A mice
compared with WT litters. Possibly, we did not see a reduction
of mature CTSD in total protein lysates because glial cells of
G93A mice express high amounts of mature CTSD at day 100 7
(Fig. 6e). However, levels of mature CTSD significantly increased
in compound 2a-treated G93A mice (Fig. 6e). We next analyzed
CTSD levels and CTSD+ puncta in MNs by confocal microscopy,
observing their significant reduction in MNs of vehicle-treated
G93A mice that was restored by treatment with compound 2a
(Fig. 6f). These data suggest that retromer stabilization mediated
by compound 2a restores Sortilin and CI-MPR expression levels
in ALS mice and improves CTSD maturation, thus restoring
lysosome health in ALS mice7,49.
Compound 2a increases lysosomal homeostasis in G93A mice.
Ubiquitinated inclusions accumulate in MNs from sALS and
fALS patients50, and in ALS mice51. We characterized poly-
ubiquitinated proteins in lumbar SCs protein extracts by 10%
denaturating PAGE. Protein extracts from Neuro2a cells treated
with the proteasome inhibitor Bortezomib (BTZ), able to increase
poly-ubiquitination, were used as an experimental control52
(Fig. 7a). Vehicle-treated G93A mice displayed abundant poly-
ubiquitinated proteins whereas their levels were substantially
reduced by compound 2a (Fig. 7b). We next scored ubiquitin MFI
levels in ventral horn MNs of G93A mice. MFI levels of ubiquitin
fluorescence in vehicle-treated G93A MNs were higher than in
compound 2a-treated G93A mice, further confirming previous
results53 (Fig. 7c and d). We next scored the Golgi apparatus in
G93A mice by labeling lumbar sections for the cis-Golgi matrix
protein GM13054. We observed that many MNs from vehicle-
treated G93A mice displayed a reduction of GM130-covered
areas, possibly indicating the organelle fragmentation55 (Fig. 7e).
However, this phenomenon was substantially reverted when we
scored MNs of compound 2a-treated G93A mice (Fig. 7e).
Lysosomal alterations are early events in ALS7,56. We
speculated that an impairment of the retromer should alter
protease trafficking via CI-MPR, and therefore disrupt lysosomal
homeostasis57. We determined whether a reduction of VPS35
levels in Neuro2a cells could affect lysosomal homeostasis,
mimicking what was observed in ALS models7,56. We transfected
Neuro2a cells with plasmids encoding the Sh56-RNAi to
downregulate VPS35. After 24 h of starvation, we analyzed the
lysosomes using Lyso-tracker58. We observed enlarged and
abnormally distributed lysosomes in cells with VPS35 inter-
ference by Sh56 (Supplementary Fig. 12a–c). We next assessed
that poly-ubiquitinated protein levels were doubled in Neuro2a
cells receiving a VPS35-targeted RNAi, suggesting that loss of
retromer functionality alters lysosomal homeostasis and the
accumulation of poly-ubiquitinated proteins (Supplementary
Fig. 12d, e)21. We asked whether the overexpression of SOD1G93A
would also result in similar lysosomal alterations by transfecting
Neuro2a cells with plasmids encoding SOD1G93A, with or
without compound 2a. After 24 h of starvation, cells receiving
only SOD1G93A plasmids showed enlarged lysosomes, while as
expected treatment with compound 2a significantly reverted this
phenotype (Supplementary Fig. 12f, g).
Compound 2a counteracts SOD1G93A proteins aggregation.
SOD1 mutations increase its propensity to aggregate in cells59.
1500
WT-vehicle G93A-vehicle
G93A-2a (10 mg/kg)
1000
D
eg
en
er
at
e 
fib
er
s/
m
m
2
500
0
WT-v G93A-v G93A-2a
a b
c d
Fig. 5 Compound 2a attenuates sciatic nerve degeneration in G93A mice. a Low and high magnifications of a sciatic nerve cross section from a vehicle-
treated WT mouse. b Low and high magnifications of a sciatic nerve cross section from a vehicle-treated G93A mouse. c Low and high magnifications of a
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We checked whether compound 2a could reduce the accumula-
tion of SOD1G93A aggregates in vivo. Starting at postnatal day 83,
we injected G93A mice and WT littermates daily with compound
2a. We scored motor performances in vehicle- and compound
2a-treated G93A mice until day 103. As expected, mice receiving
compound 2a displayed a general attenuation of motor deficits
(Supplementary Fig. 13a). We resolved SC protein extracts by
blue-native polyacrylamide gel electrophoresis60, and probing
them with anti-SOD1 antibodies we observed high molecular
weight smears in G93A mice that were absent in WT litters.
The intensity of such high MW entities was lowered in G93A
mice treated with compound 2a (Supplementary Fig. 13b, c).
These results suggest that retromer stabilization mediated
by compound 2a increases lysosomal homeostasis in vitro
WT-vehicle G93A-vehicle
G93A-2a (10mg/kg)
CI-MPR
NeuN
a b
c d
e
f
255
50,000
80,000
n.s.
60,000
40,000
20,000
0
40,000
30,000
VP
S3
5 
(M
FI,
 a.
u.)
5000 25,000
20,000
15,000
10,000
5000
0
4000
3000
10,000
8000
6000
4000
2000
0
2000
1000
0
CI
-M
PR
 (M
FI,
 a.
u.)
CT
SD
 (M
FI,
 a.
u.)
2.0
0.08
0.06
0.04
0.02
0.00
1.5
1.0
0.5
0.0
CT
SD
 (li
gh
t c
ha
in/
he
av
y c
ha
in)
CT
SD
 +
 p
un
ct
a/
Ne
uN
 a
re
a 
(μm
2 )
So
rti
lin
 (M
FI,
 a.
u.)
VP
S2
6 
(M
FI,
 a.
u.)
20,000
10,000
0
0
255
0
255
0
255
0
255
0
WT-v. G93A-v. G93A-2a WT-v. G93A-v. G93A-2a
WT-v. G93A-v. G93A-2a
WT-v. G93A-v. G93A-2a WT-v. G93A-v. G93A-2a
WT-v. G93A-v. G93A-2a
WT-v. G93A-v. G93A-2a
WT-vehicle
38
31
38
G93A-vehicle G93A-2a (10 mg/kg)
CTSD Heavy
chain
CTSD Light
chain
β-Actin
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17524-7 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:3848 | https://doi.org/10.1038/s41467-020-17524-7 | www.nature.com/naturecommunications 9
and in vivo, decreases protein polyubiquitination and diminishes
G93A aggregation.
VPS35 expression in ASL SCs and in iPSCs-derived MNs from
ALS fibroblasts. We investigated VPS35 expression in human
MNs located in the ventral horn of the SC (Fig. 8a). VPS35
immunoreactivity was substantially reduced in ALS MNs, con-
firming our observations in G93A mice (Fig. 8b). Parallel sections
probed for VPS26 revealed a substantial reduction of VPS26
immunoreactivity in ALS samples (Fig. 8c, d).
We next generated iPSC lines from fibroblasts obtained from
fALS patients carrying three SOD1 gene variants (ALS 8: p.
Asn65Ser; ALS 13: p.Leu144Phe; ALS 27: p.Asp97Asn), and from
three healthy volunteers. Efficient reprogramming was assessed
by labelling cultures for OCT3/4, SOX2, NANOG, TRA1-60, and
SSEA4 (Supplementary Fig. 14). We observed a normal karyotype
in ALS cell lines (Supplementary Fig. 15a). According to
literature61 we induced the phenotype of caudal neuroepithelial
OLIG2+PAX6− progenitors in iPSCs (Supplementary Fig. 15b,
c), and we differentiated them to acquire the OLIG2-ISLET1+ cell
phenotype. We scored the ISLET1+ percentage among nuclei,
observing similar rates of cell differentiation among controls and
ALS cells (controls: 81.6% ± 9; ALS: 81.8% ± 12, Supplementary
Fig. 15d, e). Using immunofluorescence and WBs, we observed
that VPS35 levels in ISLET1+ MNs were reduced in ALS samples
(Fig. 8e, f). We next selected a control cell line (#8) and an ALS
cell line (ALS 27) for compound 2a treatment. After establishing
OLIG2+PAX6− progenitors, we differentiated these cells in
presence of compound 2a (10 µM, 6 days). Cells were labelled
for ISLET1 and VPS35 and by confocal microscopy, and we
scored VPS35+ puncta. ALS 27 cells displayed less VPS35+
puncta than controls, albeit both cell types significantly increased
VPS35+ puncta when treated with compound 2a (Fig. 8g). We
next used WB for o confirm the ability of compound 2a to
increase VPS35 protein levels in ALS cells (Fig. 8h). Altogether,
these results suggest that compound 2a can be used to stabilize
the retromer complex in ALS models.
Discussion
We describe a substantial reduction of CRC proteins in MNs of
G93A mice. Similarly, we observe a reduction of VPS35 levels in
MNs scored in postmortem ALS patients, and in human iPSC-
derived MNs from fALS patients. As retromer failures occur in
AD62 and PD17 neurons, we speculate that the reduction of ret-
romer levels observed in ALS represents one among many
aberrant responses and deficits that affect neurons overwhelmed
by misfolded/aggregated proteins.
This alteration occurs early in G93A mice, suggesting that the
retromer could be an early therapeutic target in ALS, albeit future
investigations are needed to identify mechanisms leading to ret-
romer failure in ALS MNs.
The CRC core element of the retromer and the SNX dimer
assemble to create a functional retromer complex8,22,61. Knock-
down of a single CRC protein affects the expression of the other
CRC members15,21. On the other hand, strengthening the inter-
action between proteins assembled in the CRC bolsters full ret-
romer stability, and increases its functionality as elegantly
described20.
Compounds binding to the interface between VPS35 and
VPS29 and stabilizing the retromer assembly were identified by
virtual screening. Among them, bis-isothiourea R55/1 increased
VPS35 levels (∼60%) in cells, and therefore the general stability of
the retromer complex20. Treatment of neurons carrying patho-
genic APP mutations with R55/1 reduced the accumulation of
amyloid-β (Aβ) peptides as well as APP processing20.
We designed and synthesized a small array of phenyl bis-
guanylhydrazone chaperones that interact with the CRC complex
at the VPS35-VPS29 interface, as R55/1. We selected compound
2a, due to its ability to increase VPS35 levels in Neuro2a cells and
to cross the BBB. Through STD-NMR and WL-NMR experi-
ments we experimentally proved the binding of 2a to the VPS29-
VPS35 heterodimer.
We assayed compound 2a in vitro by overexpressing
SOD1G93A in cells. The overexpression of mutant SOD1 increases
rates of cell death in MN-like NSC-34 cells5, and SOD1G93A
affects Neuro2a cell survival63. Compound 2a significantly
counteracted cell death and reduced LDH release in Neuro2a cells
transfected with SOD1G93A plasmids. Although we cannot rule
out the possibility that compound 2a modulates additional targets
other than the CRC, we observed that it failed to rescue Neuro2a
cell survival and to inhibit LDH release in presence of VPS35-
targeted siRNA.
We used compound 2a to restore retromer levels in G93A
mice. Transgenic mice and their WT litters well tolerated
Fig. 6 Compound 2a increases retromer proteins in G93A mice. (a–d, f) maximum projections of confocal stacks from lumbar SCs (ventral horn) of
vehicle-treated WT, vehicle-treated G93A and compound 2a (10mg/kg, day 100)-treated G93A mice (n= 3 independent mice/group) labelled for:
VPS35/NeuN (a), VPS26/NeuN (b), CI-MPR/NeuN (c), Sortilin/NeuN (d), and CTSD/NeuN (f). Averaged fluorescence intensities (MFI) in gated NeuN+
MNs (WT-v: n= 38 independent MNs, G93A-v: n= 54 independent MNs, G93A-2a: n= 42 independent MNs, data were examined from three
independent experiments), of VPS35 (Alexafluor 488) are reported as mean arbitrary units (a.u. ± SEM) in Panel a (WT-v vs. G93A-v p= 0.002, WT-v vs.
G93A-2a p= 0.046, G93A-v vs. G93A-2a p= 0.011). Averaged MFI (a.u. ± SEM) of VPS26 (Alexafluor 488) quantified in gated NeuN+MNs (WT-v: n=
40 independent MNs, G93A-v: n= 54 independent MNs, G93A-2a: n= 40 independent MNs, data are examined from three independent experiments)
are shown in b (G93A-v vs. G93A-2a p= 0.09, other comparisons p < 0.0001). Averaged MFI of CI-MPR (Alexafluor 488, a.u. ± SEM) in NeuN+ MNs
(WT-v: n= 31 independent MNs, G93A-v: n= 31 independent MNs, G93A-2a: n= 33 independent MNs, data are examined from three independent
experiments) are shown in c (G93A-v vs. G93A-2a p= 0.026, other comparisons p < 0.0001). Averaged Sortilin MFI levels (Alexafluor 488 a.u. ± SEM)
quantified in gated NeuN+ MNs (WT-v: n= 33 independent MNs, G93A-v: n= 37 independent MNs, G93A-2a: n= 38 independent MNs, data are
examined from three independent experiments) are shown in d. Epi-fluorescence scales are shown on the right side of a–d (WT-v vs. G93A-2a p= 0.009,
other comparisons p < 0.0001). e Representative WB for CTSD (heavy (46–50 KDa) and light (28–30 KDa chains). Normalization of proteins load was
done by β-Actin. The histogram in e shows quantifications (WT-v: n= 7 independent mice, G93A-v: n= 8 independent mice, G93A-2a: n= 8 independent
mice, data are examined from two independent experiments; lines show mean+ SEM). WT-v vs. G93A-2a p= 0.02, G93A-v vs. G93A-2a p= 0.0032.
f Averaged CTSD MFI levels (Alexafluor 488, a.u. ± SEM) in gated NeuN+ MNs (WT-v: n= 42 independent MNs, G93A-v: n= 54 independent MNs,
G93A-2a: n= 63 independent MNs, data are examined from three independent experiments). The epi-fluorescence scale is shown in f (WT-v vs. G93A-2a
p= 0.011, other comparisons p < 0.0001). Numbers of CTSD puncta normalized for the area of NeuN+ MNs are shown in the histogram (WT-v: n= 3
independent mice, G93A-v: n= 3 independent mice, G93A-2a: n= 4 independent mice, data are examined from two independent experiments, lines show
mean+ SEM). (WT-v vs. G93A-v p= 0.0005, G93A-v vs. G93A-2a p= 0.006. One-way ANOVA followed by Tukey's Multiple Comparison test was used
to analyze data in a–f. *p < 0.05, **p < 0.01, ***p < 0.001. Scale bars 30 µm for a, b, d, and f; 25 µm for c.
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intraperitoneally delivered compound 2a, as we did not observe
distress, aberrant behavior or pain in treated mice. This in vivo
observation is coherent with in vitro low toxicity of compound
2a, and with the absence of toxic effects in mice expressing AAV-
VPS3543.
Neurons cannot divide, and therefore cannot dilute cyto-
plasmic misfolded/aggregated proteins that accumulate. Their
removal is a complex task involving recognition proteins, cha-
perones, and eventually activation of degradation pathways such
as the ubiquitin-proteasome system and the autophagy-lysosomal
pathway64, both altered in ALS. Mutant SOD1 proteins associate
with reduced expression of components of the ubiquitin-
proteasome system65. C9orf72, an ALS causative gene, is a reg-
ulator of autophagy66 and a keeper of lysosome homeostasis67.
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Lysosomal deficits are well documented in G93A mice and
starting from day 40, the levels of CTSD are significantly reduced
in MNs7 from these mice. The maturation of this lysosomal
enzyme involves CI-MPR and a functional retromer21. We
observed increased levels of both CI-MPR and CTSD in MNs of
G93A mice treated with compound 2a. Therefore, we hypothe-
sized that increasing retromer stabilization could increase the
delivery of CTSD to the lysosomal compartment and finally the
lysosomal functionality. These data are far from conclusive, and
further experiments aimed to inactivate CTSD in G93A mice are
needed to investigate its contribution to the degradation of mis-
folded proteins.
Golgi fragmentation is commonly observed in MNs of sALS
and fALS patients35,68. Using compound 2a we observed a sub-
stantial attenuation of Golgi fragmentation in SOD1G93A over-
expressing cells and in G93A mice. The mechanism(s) that
connect retromer stabilization to the rescue of Golgi fragmenta-
tion are unknown, although experimental evidence suggests a
functional link between a protein belonging to Vesicle Associated
Membrane Protein (VAMP)-associated proteins (VAP) VPSs and
Golgi homeostasis. A mutant form of VAP-B (P56S) was
described in a family of ALS patients69, and VAP-B levels are
dampened in MNs of G93A mice70. The retromer complex
interacts with VAP-B and such interaction occurs in regions in
which the ER makes contacts with endosomes71. It is tempting to
speculate that increasing the retromer stability with compound
2a, we can also restore VAP-B functionality, indirectly restoring
homeostasis. Further investigations will help to dissect the
interaction between VAPs and retromer in ALS mice.
Compound 2a attenuated locomotion impairment in G93A
mice, and significantly increased the number of surviving MNs.
These functional effects correlate with the ability of 2a to increase
CRC protein levels in MNs, but further experiments with VPS35
conditional KO mice will further validate in vivo the mechanism
of action of compound 2a.
Lysosomal alterations probably concur to increase the accu-
mulation of poly-ubiquitinated proteins in the lumbar SC72. Such
pathological phenomenon was significantly reduced in vitro and
in vivo by compound 2a. We do not know whether retromer
failure is the leading trigger inducing the loss of lysosomal
functionality in ALS, but we observed that either VPS35 knock-
down or overexpression of SOD1G93A in Neuro2a cells increased
poly-ubiquitinated protein levels. We acknowledge that failure of
the retromer complex could lead to lysosomal deficits, autophagy
alteration and exaggerated protein poly-ubiquitination by syner-
gizing with other detrimental pathways operating in the ALS
pathophysiology. Similarly, G93A mice receiving compound 2a-
driven retromer stabilization showed a substantial reduction of
high molecular weight SOD1 aggregates.
Therefore, pharmacological retromer stabilizers could be useful
to delay degenerative processes occurring in ALS.
Methods
Docking experiments. The docking analysis was performed with
AutoDock4.2 software73 building the coordinates of the VPS29-VPS35 hetero-
dimer74 (pdb-id 2r17). Each ligand was drawn with the program “Marvin Sketch
v20.13.0” (Chemaxon packages; https://chemaxon.com/), converted in a 3D
structure and then transformed in the pdbqt format with the addition of partial
charges and rotatable bonds (http://mgltools.scripps.edu). A cubic docking grid
centered around the side chain of Gln530 of VPS35 with 15 Å side length was used
for explorations. We performed 40 independent, global-local Lamarkian genetic-
algorithm runs for each tested compound, extracting the conformation, the binding
energy and the calculated Kd of the best pose together with the number of poses
clustered around such best conformation (Python Molecular Viewer http://
mgltools.scripps.edu). Additionally, we utilized a sigmoidal rectification function
shown in Supplementary Fig. 4a to weight the calculated Kd with recurrence of best
docking poses and generate a normalized Kd, as explained in the main text.
Druggability parameters. pKa and clogP values were calculated using the “Cal-
culator Plugins” module of the ChemAxon's Marvin suite (https://chemaxon.com/
marvin-archive). We used the default parameters without any correction.
Synthesis. General procedures: 1H-NMR spectra were recorded on a Bruker
Avance 400 MHz instrument in CDCl3, CD3OD, or D2O as solvent at 400 MHz.
13C-NMR spectra were recorded in CDCl3, CD3OD, or D2O as solvent at 101 MHz.
Coupling constants are expressed in Hertz and are rounded to the nearest 0.1 Hz.
LC-MS data were collected with a Waters AcquityTM Ultra performance LC
equipped with an Acquity UPLCTM HSS T3 column (2.1 × 50 mm, 1.8 µm) and a
SQD detector. Purifications were carried out either by flash chromatography on
silica gel (particle size 60 μm, 230–400 mesh), on Kieselgel, or by BiotageTM flash
chromatography [Biotage columns Si-25-M (150 × 25 mm; silica gel (40–63 μm),
flow rate 25 mL/min)], or by BiotageTM C18 reverse phase chromatography [Bio-
tage column C18HS (150 × 25 mm; KP-C18-HS (35–70 μm), flow rate 25 mL/min)].
Some final compounds were purified by C18 reverse phase semi-preparative HPLC
using a Waters X-Bridge column (19 mm × 15.0 cm, 5 μm). Melting points were
determined with a Stuart Scientific SMP3 melting point apparatus. Solvents were
distilled and dried according to standard procedures, and reactions requiring
anhydrous conditions were performed under nitrogen or argon atmosphere.
Synthesis of bis-1,3-phenyl guanylhydrazone 2a. Compound 2a (280 mg, 0.88
mmoles, 88% yield, ≥95% purity, m.p. 200–202 °C, white solid) was prepared in a
single step from commercially available isophthalic aldehyde and aminoguanidine
dihydrochloride. Diode Array LC trace, TIC trace and ES scan for compound 2a
are available in Supplementary Fig. 4e; 1H-NMR and 13C-NMR are provided in the
Supplementary Fig. 4f and g, respectively.
Animals and treatments. Mice were maintained under pathogen-free conditions
at San Raffaele Hospital mouse facility (Milan, Italy). All efforts were made to
minimize animal suffering and to reduce the number of mice used in accordance
Fig. 7 Compound 2a reduces protein ubiquitination in G93A mice. a Representative WB for poly-ubiquitinated proteins in experimental controls: Neuro2a
cells (3 × 105 cells/well) treated with sham or with Bortezomib (10 nM, BTZ); and in lumbar SC extracts from vehicle-treated WT mice, vehicle-treated
G93A mice and compound 2a-treated G93A mice (10mg/kg, day 100). Normalization of proteins load was done by β-Actin. Dividing black lines show
lanes cropped from independent filters. b Collective densities of lanes, normalized for β-Actin, were used for quantification (n= 7 independent mice/group
data are examined from three independent experiments, lines show means+ SD). WT-v vs G93A-2a: p= 0.013, p < 0.0001 for the other comparisons.
c Maximum projections of confocal stacks from lumbar SCs sections of vehicle-treated WT, vehicle-treated G93A and compound 2a-treated G93A mice
(10mg/kg, sampled at day 100) labelled for ubiquitin (Ubi) and NeuN (n= 3 independent mice/group). Averaged fluorescence intensities (MFI, lines
show means+ SEM) in gated Neun+MNs of Ubi (Alexafluor 488) are reported in d (arrows indicate representative cells; WT-v: n= 20 independent MNs,
G93A-v: n= 35 independent MNs, G93A-2a: n= 31 independent MNs, data are examined from three independent experiments; WT-v vs. G93A-2a: p=
0.014, p < 0.0001 for the other comparisons). The epi-fluorescence scale is shown in right side. eMaximum projections of confocal stacks (step of 0.4 µm)
of MNs labelled for NeuN and GM130. Arrows in each panel indicate regions showed at high magnification in insets. Quantifications (means ± SEM) of
GM130 area are shown in upper e, (WT-v: n= 43 independent MNs, G93A-v: n= 36 independent MNs, G93A-2a: n= 36 independent MNs, data are
examined from three independent experiments; G93A-v vs. G93A-2a: p= 0.0018; p < 0.0001 for the other comparisons). Quantifications of GM130
distribution (mean% of the cell area ± SEM) are shown in lower panel e, (WT-v: n= 40 independent MNs, G93A-v: n= 31 independent MNs, G93A-2a:
n= 31 independent MNs, data are examined from three independent experiments; WT-v vs. G93A-2a: p= 0.63, p < 0.0001 for the other comparisons).
One-way ANOVA followed by Tukey's Multiple Comparison test was used to analyze data of b–e. *p < 0.05, **p < 0.01, ***p < 0.001, n.s. not significant.
Scale bar 50 µm in c and 20 µm in e.
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with the European Communities Council Directive of 24 November 1986 (86/609/
EEC). The Ethics Review Committee approved experimental protocols according
guidelines from the Italian Ministry of Health and from the Institutional Animal
Care and Use Committee of the San Raffaele Scientific Institute (protocol number
704/2015PR). Transgenic mutant SOD1 mice carrying the SOD1G93A allele (strain
B6SJL-TgN[SOD1G93A]1GUR)75 were purchased from Jackson laboratories, while
C57BL/6J mice, used for breeding and experimental purposes, were purchased
from Charles River (Italy). Both transgenic and WT mice had food and water freely
available in the home-cage. The holding room was on a 12-h light–dark cycle, the
temperature of the room was 22 ± 0.2 °C. Starting from day 30 we intraperitoneally
injected compound 2a (10 mg/Kg) or vehicle in G93A mice as well as in C57BL/6J
mice for 70 days. Additional experiments were performed injecting mice from day
83 to day 103. An operator blind to the treatment performed injections and
manipulation of mice. At the day of the sacrifice, mice received an overdose of
anesthetic drugs and they were perfused via vascular system with saline followed
by 70–80 ml 4% paraformaldehyde (PF) in PBS, pH 7.2 (Sigma–Aldrich). Spinal
cords were coronally sliced at ~6-mm thickness and postfixed in 4% PF in PBS,
pH 7.2 for 12 h at +4 °C. Tissues were cryoprotected in PBS 1X/30% Sucrose
(Sigma–Aldrich), embedded in OCT inclusion media and stored at −80 °C before
processing. Lumbar spinal cords were 12-µm sectioned, labelled and digital images
were acquired every 330 µm in a region encompassing 2.4 mm of the lumbar spinal
cord. We determined numbers of mice by preliminary results or literature
precedent76.
Motor function. Motor activity of mice receiving compound 2a or vehicle was
assessed on 50-, 60-, 70-, 80-, 90-, and 100-days-old animals. Briefly, mice were
trained 1 min on a static rotor and 1 min at constant speed (4 rpm) for two times
and then we ran two trials performed over two consecutive days (one per day).
Each trial consisted of 6-test sessions with 15 min interval between sessions. For
each session, we placed mice on an accelerating rotor (4–40 rpm) and the latency to
fall was recorded, with a maximum limit for individual animal set at 600 seconds.
Mass spectrometry quantitative analysis of compound 2a. Quantification of
compound 2a in CNS extracts of C57BL/6J mice was performed at ProMeFa
facility (Proteomics and Metabolomics Facility) of San Raffaele Scientific Institute.
Wild-type C57BL/6J males mice (P60) were intraperitoneally injected with com-
pound 2a (10 mg/kg) or vehicle, daily. We sacrificed mice at the following time
points: 1, 7, 15, and 30 days. Before brains collection, mice received saline perfu-
sion. Brains were weighted (~350 mg each) and rapidly frozen at −80 °C. The
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Fig. 8 VPS35 levels in ALS iPSCs-derived MNs and postmortem biopsies. a, b IHC for VPS35 in alpha-MNs in representative sections from ventral horns
of SCs biopsies from a non-neurological control (a) and an ALS patient (b). c, d, IHC for VPS26 in alpha-MNs sampled in adjacent sections from a non-
neurological control (c) and an ALS patient (d). Analyses were done on four non-neurological control biopsies and five ALS biopsies examined over three
independent experiments. e Maximum projections of representative confocal stacks (three independent experiments) for VPS35 and ISLET1 in
representative cultures of iPSC-derived MNs from a healthy volunteer (#8) and an ALS patient (#13SOD1Leu144Phe). A representative WB for VPS35 and β-
Actin in protein extracts from iPSCs-derived MN cultures (#8 SOD1Asn65Ser, #13SOD1Leu144Phe, #27 SOD1Asp97Asn and age- and sex-matched healthy
volunteers #2, #4, and #8) is shown in f. Quantifications derived from n= 3 controls (#2, #4, and #8) and from n= 3 ALS (#8, #13, and #27), means
(±SD) are examined from two independent experiments (p= 0.005). g Representative cross-sectional analysis of confocal stacks (three independent
experiments) for VPS35 and ISLET1 in cultured iPSCs-derived MNs from an healthy volunteer (#8) and from an ALS patient (#27 SOD1Asp97Asn) with
or without compound 2a (10 µM for 6 days). h Representative WB for VPS35 and β-Actin in iPSCs-derived MNs of an ALS patient (#27) treated with
vehicle or with compound 2a (10 µM for 6 days). Quantifications (means ± SD) derived from n= 3 wells/treatment and data are examined from one
experiment (p= 0.017). Two-tailed Student’s t-test was used to determine the statistical significance in f and h. **p < 0.01. Scale bar: 150 µm in d, 25 µm in
e, 15 µm in g.
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extraction was performed with methanol and each biological sample was resus-
pended in 60 µl of LC/MS grade water and 5 µL were analyzed by LC-MS/MS using
the UPLC 1290 (Agilent Technologies) coupled to the TripleTOF 5600+ mass
spectrometer (SCIEX). The mass spectrometry analysis was carried out in positive
mode, in the range of 50-500 m/z for both the TOF-MS scan and the product ion
scan, with a selected product ion of 247.1. A Waters ACQUITY UPLC BEH HILIC
column (2.1 × 10mm, 1.7 µm) was used for the chromatographic separation
through a gradient of solvent A (acetonitrile + 0.1% formic acid) and solvent B
(water + 0.1% formic acid) from 2% up to 29% B in 5 minutes with a flow rate of
600 µl/min. Calibration curve in brain was constructed by plotting the peak area
versus corresponding quantities of compound 2a (0; 0.1; 0.26; 1 nmol, run in
quadruplicates, R2= 0.9443), using MultiQuant 2.1 software (SCIEX).
NMR spectroscopy. NMR spectra were acquired at 298K on a Bruker Avance
NEO 700 MHz spectrometer equipped with a Z-gradient cryoprobe. The spectra
were processed with the Bruker TOPSPIN 4.0.5 software packages. For NMR
studies of compound 2a with VPS29-VPS35, 5 μl from a DMSO-d6 stock 20 mM
solution were dissolved in 175 μl of buffer (50 mM KH2PO4, 50 mM Na2HPO4, pH
8.0, 150 mM NaCl, 2 mM DTT) and 20 μL of 2H2O. Saturation Transfer Difference
spectra (1H spectral window= 16 ppm; relaxation delay= 3.0 s; number of points
= 32K) were acquired with 1024 scans with on-resonance irradiation at −1.0 ppm
for selective saturation of protein resonances, and off-resonance irradiation at 40
ppm for reference spectra. A train of 40 Gaussian shaped pulses of 50 ms with 1 ms
delay between pulses were used, for a total saturation time of 2 s. 1D 1H spectra
were recorded using a 1 s presaturation pulse with a B1 power of 200 Hz.
WaterLOGSY experiments (WL) were acquired using the ePHOGSY sequence33.
WL experiments (1H spectral window= 16 ppm; relaxation delay= 3.0 s; number
of points= 16K, scan= 1024) employed a 20 ms selective Gaussian 180° pulse at
the water signal frequency and a NOE mixing time of 1 s. Both for STD and
WaterLOGSY, FIDs were multiplied by an exponential weighting (lb= 5 Hz)
before Fourier transformation.
Cell lines, culture conditions, and treatments. Neuro2a cells (ATCC® CCL-131™)
were seeded in Dulbecco’s modified Eagle’s media (DMEM, Gibco) supplemented
with FBS 10% (Gibco), L-glutamine (Gibco) 2 mM and penicillin/streptomycin 1%
(Gibco). Depending on the experimental setting, we used 6-well, 12-well or 96-well
dishes. Neuro2a were grow at 37 °C in a humidified 5% CO2 atmosphere. All
experiments were carried out at least in triplicate. Compounds and transfections
were done on cells showing 60–70% of confluence. Compounds were usually kept
on cells for 48 h; Bortezomib (BTZ) was used at 10 nM for 6 h to inhibit protea-
some. Transient transfections were obtained using lipofectamin LTX reagent
(Thermofisher) with the following plasmids: pCMV-LacZ; pcDNA3.1(+)
SOD1G93A;77 pcCDNA3.1(+)VPS35; pCAAG-GFP according the manufacturer’s
instructions.
VPS35 short interference: we used Lipofectamine LTX (Thermofisher) to
transfect Neuro2a cells with the following plasmids: plKO short interference
scramble; TRCN0000111556 (Sh56); TRCN0000111558 (Sh58); TRCN0000111559
(Sh59), (Mission, Sigma–Aldrich). Protein and total mRNA extracts were obtained
according the experimental design.
Cell survival experiments were run on 96-well plates using Cell Counting Kit-8
(CCK8) survival kit (96992-Sigma–Aldrich) according the manufacturer’s
recommendations. Compound 2a cytotoxicity was tested on Neuro2a cells
receiving increasing amounts of compound 2a (1, 10, 50, 100, 200, 500, and 1000
µM) for 48 h. Data were acquired using an Epoch spectrophotometer equipped
with the GEN5 (2.03.1) software (Agilent).
LDH cytotoxicity was run on 96-well plates using LDH-Glo™ Cytotoxicity Assay
(Promega). Briefly, Neuro2a cells were transfected with plasmids encoding pCMV-
LacZ; pcDNA3.1(+)SOD1G93A77 with or without VPS35 short interfering
plasmids (Sh56) or compound 2a (10 µM). After 48 h, 5 µl of supernatants were
100-fold diluted in LDH storage buffer (Tris-HCl 200mM, 10% Glycerol, 1% BSA,
Sigma–Aldrich) and used to determine LDH, according to manufacturer’s
recommendations. Maximum LDH Release Control was obtained lysing untreated
Neuro2a cells with 2 μL of 10% Triton X-100 (Sigma–Aldrich). In each experiment
we calculated% cytotoxicity ¼ Exp:LDH releasemedium backgroundMax LDH release controlmedium background, and we run
parallel positive controls treating cells with 200 µM H2O2. Data were acquired
using a Victor3 spectrophotometer equipped with Wallac 1420 software
(PerkinElmer)
Cycloheximide (CHX) assay was done on Neuro2a cells seeded in 6-well plates
and incubated with compound 2a (10 µM) or vehicle for 24 h. We next added CHX
(Sigma–Aldrich) at 10 µg/mL and cells were collected at 0, 2, 4, and 8 h for the
time-course assay of VPS35 levels by WB.
Generation of human iPSC lines and derived MNs. Skin biopsies from ALS
patients and healthy volunteers were performed under local anesthesia, after
informed consent at San Raffaele Hospital (BANCA INSPE/8-10-19 and MND
Genotipo Fenotipo/16-5-19, approved by the Ospedale San Raffaele Etic Com-
mittee). Primary fibroblasts were grown in Dulbecco’s modified Eagle’s medium
with Glutamax I (GIBCO). Human iPS cell lines were generated using non inte-
grating Sendai virus, maintained in feeder-free conditions in mTeSR-1 (Stem Cell
Technologies) on embryonic stem cell (HESC) Matrigel (Corning). MNs were
generated following the protocol published by Du et al.78 with minimal mod-
ification. Briefly, when hiPSCs reached confluence, they have been detached using
EDTA and plated 1:4 on Matrigel ES coated dishes in mTeSR-1 supplemented
with ROCK inhibitor (StemMACS, Miltenyi Biotec). On the following day the
medium was replaced with a chemically defined neural medium: DMEM/F12,
Neurobasal medium at 1:1 ratio, 1% B27, 0.5% N2 (all from Gibco, ThermoFisher
Scientific), 1% P/S (Gibco), 1% Glutamax (Gibco) and 0.1 mM Ascorbic Acid
(Sigma–Aldrich). CHIR99021 (3 μM, Tocris), DMH1 (2 μM, Tocris) and SB431542
(2 μM, Miltenyi Biotec) were added to the medium. The culture medium was
changed every other day, until day 6. On day 7, cells have been dissociated with
Dispase (1U/mL), split 1:4 and kept on Matrigel growth factor reduced (MaGR)
for 6 days in the basal neural medium described above, supplemented with
1 μM CHIR99021, 2 μM DMH1, 2 μM SB431542, 0.1 μM Retinoic Acid (RA,
Sigma–Aldrich) and 0.5 μM Smoothened Agonist, (SAG, Calbiochem). On day 13,
cells have been dissociated with Dispase (1U/mL), split 1:4, and kept for 6 days in
neural medium supplemented with 3 μM CHIR99021, 2 μM DMH1, 2 μM
SB431542, 0.1 μM RA, 0.5 μM SAG, and 0.5 mM Valproic Acid (VPA, Tocris). To
induce MN differentiation, cells were dissociated with Dispase (1U/mL) and cul-
tured in suspension for 6 days in neural medium with 0.5 μM RA and 0.1 μM SAG.
On day 25, cells were dissociated into single cell with Accumax (Sigma–Aldrich)
and plated on Matrigel Growth Factor Reduced (Thermofisher) coated plates, in
neural medium with 0.5 μM RA, 0.1 μM SAG, 0.1 μM Compound E (Calbiochem)
until day 35. Half of the medium has usually been changed every other day. The
karyotyping analysis was performed by ISENET Biobanking service unit in Milan,
Italy (www.isenetbiobanking.com).
Immunoblotting. Lumbar SCs were dissected after mice received saline perfusion
and were rapidly homogenized in the following lysis buffer: Tris-HCl 10 mM pH 8,
EDTA pH 8 1mM, NaCl 100 mM, NP40 1% and protease inhibitor cocktail
(Sigma–Aldrich). Protein extracts were obtained using a tight-fitting glass Potter
tissue grinder (1 mL; Wheaton) and then sonicated at a frequency of 20 kHz (10
times-1s). Protein lysates from cells cultures were collected from plates receiving
PBS 1× washing and subsequently the lysis buffer followed by sonication. Protein
concentrations were measured by BCA protein assay kit (Thermofisher) according
to the manufacturer’s recommendations. Ten µg of protein extract was loaded on
10% Mini-PROTEAN TGX Stain-Free precast gels for PAGE (Bio-Rad). Gel
electrophoresis was performed at 100 V for 2 h. Gels were transferred on Immo-
bilon®-P PVDF membrane according to the manufacturer’s instructions (Milli-
pore). Blots were blocked in 5% BSA in Tris buffered saline plus 0.1% Tween-20
(TBS-T) for 1 h before receiving primary antibodies: goat α-VPS35 1:800 (ab10099,
Abcam); rabbit α-VPS26 1:1000 (ab23892 Abcam), rabbit α-VPS26b 1:1000
(15915-1-AP, ProteinTech); rabbit α-VPS29 1:1000 (ab236796 Abcam); mouse α-
βActin 1:25000 (Sigma–Aldrich); mouse α-Golgin97 1:1000 (Invitrogen); mouse α-
Ubiquitin 1:500 (Merk); rabbit α-CD14 1:1000 (Bioss Inc); mouse α-Tubulin
1:5000 (Immunological Sciences MAB-80143) overnight at 4 °C on shaker. Fol-
lowing several washes with TBS-T, blots were incubated in appropriate HRP-
labeled secondary antibodies (Bio-Rad) for 1 h at room temperature. Visualization
of protein bands was obtained using ClarityMax-ECL (Bio-Rad) according to the
manufacturer’s instructions and images were acquired on ChemiDoc (Bio-Rad).
Quantifications were done using the Image Lab 6.0.1 software (Bio-Rad).
Blue-Native gel electrophoresis. G93A mice and their WT litters were injected
daily with vehicle or compound 2a (10 mg/kg, from day 83 to day 103). Lumbar
spinal cords dissected from saline-perfused mice were lysed in Tris-HCl 10 mM pH
8, EDTA 1mM pH 8, NaCl 100 mM, NP40 1% and protease inhibitor cocktail
(Sigma–Aldrich). Extracts were obtained using a tight-fitting glass Potter tissue
grinder (1 mL; Wheaton). We incubated 250 µL of each extract with 100 mM
Iodoacetamide (Sigma–Aldrich). Samples were mixed with 4× Sample NativePAGE
(Thermofisher) sample buffer and the G-250 additive (Thermofisher) and proteins
were resolved on native 4–15% Bis-Tris gel (Bio-Rad) with Dark Blue Cathode
buffer (Thermofisher) at 150 V for 1/3 of gel length. We replaced the running
buffer with Light Blue Cathode Buffer to complete the run. At the end of the
electrophoresis, gels were washed with 5 mM tris(2-carboxyethyl)phosphine
(Sigma–Aldrich) for 15 min and then proteins were transferred to nitrocellulose
and fixed on the membrane by 8% acetic acid for 15 min. Rabbit α-SOD1 (1:2000,
Genetex) was incubated overnight as above described. Visualization of proteins was
performed using ClarityMax-ECL (Bio-Rad) according to the manufacturer’s
instructions and images were acquired on ChemiDoc (Bio-Rad).
Immunohistochemistry, immunofluorescence, and morphometric analyses.
Paraffin embedded SCs were obtained from ALS patients and non-neurological
controls from the Target ALS Human Postmortem Tissue Core. Sections were
stored at the INSPE tissue Bank (San Raffaele Scientific Institute). Sections were
incubated with a polyclonal VPS35 antibody (1:400 Abcam ab97545) and with the
polyclonal VPS26 antibody (1:200, Abcam ab23892) after rehydration and antigen
retrieval (slides were cooled at 97 °C in TRIS EDTA pH= 9 by water bath).
Peroxidase-diaminobenzidine (DAB) reaction was used for detecting primary
antibody, biotinylated anti-rabbit IgG (H+L) (1:500 Vector laboratories) and
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avidin-biotin complex (ABC 1:100 Vector laboratories). An operator that was blind
to the disease status and demographic data subsequently evaluated these sections.
Sections from mice or glass covers containing cells were washed three times in
PBS 1× (Lonza, 5 min each), and incubated in the following blocking mix: PBS 1×/
FBS 10% (Invitrogen), BSA 1mg/mL (Sigma–Aldrich), TritonX100 0.1% (Sigma
Aldrich), for 1 h at room temperature. Antibodies were diluted in blocking mix and
incubated at +4 °C overnight according manufacturer’s instructions. The following
day, sections were rinsed in PBS and fluorescent secondary antibodies—i.e. never
deriving from the species from which the primary antibodies are derived-
(Alexafluor conjugated) diluted in blocking mix, were used according to the
manufacturer’s instructions. Slides were incubated in Hoechst 33342
(Sigma–Aldrich) for nuclei counterstaining. When necessary, we performed
antigens retrieval on tissue sections by boiling samples in 10 mM sodium citrate
(pH 6) for 5 min. The following antibodies and working concentrations were used:
rabbit α-Iba1 1:500 (Wako); rabbit α-VPS35 1:1000 (ab97545 Abcam); goat α-
VPS35 1:800 (ab10099 Abcam); rabbit α-VPS26 1:1000 (ab23892 Abcam); rabbit α-
Sortilin 1:1000 (ab16640 Abcam); mouse α-CI-MPR 1:100 (Novus bio. NB-300-
514), mouse α-NeuN 1:800 (Millipore MAB377); mouse α-Ubiquitin 1:500
(Millipore MAB1510); mouse α-Golgin97 1:700 (Thermofisher A21270); rabbit α-
ISLET1:1000 (ab20670 Abcam); goat α-ChAT 1:200 (Millipore ab144p); chicken α-
GFP 1:1000 (Invitrogen); α-SOX2 1:100 (R&D, MAB2018); goat α-NANOG 1:200
(R&D, AF1997); mouse α-OCT3-4 1:500 (Santa Cruz, sc-5279); mouse α-SSEA4
1:400 (Millipore MAB4304); mouse α-TRA1-60 1:200 (Millpore MAB4360);
chicken α-Neurofilament-medium 1:500 (Biolegend PCK-593P); rat α-MBP 1:100
(kindly provided by Dr. A. Bolino); mouse α-GM130 1:100 (BD biosciences,
610823); rat α-CTSD 1:100 (R&D system MAB1029). Tyramide Signal
Amplification (TSA, PerkinElmer) was used, when appropriate, to improve
fluorescent intensity in single and double immunofluorescence.
Quantification of nerves degeneration was done on sciatic nerves obtained from
saline-perfused mice. Tissues were fixed in 2% buffered glutaraldehyde
(Sigma–Aldrich), postfixed in 1% osmium tetroxide and cut to obtain 1 µm thick
sections. We stained sections with toluidine blue and specimens were blindly
examined by light microscopy using ×40 objective. For each nerve, we merged
images to obtain the entire nerve cross section. Five consecutive nonoverlapping
semi-thin sections from each sample were analyzed with NHI-Image J software (US
National Institutes of Health). Degenerating fibers were counted in the entire nerve
cross section.
Quantification of myelin was done on sagittal sciatic nerves by Luxol fast blue
(LFB). Briefly, nerve sections were incubated the ethanol series before receiving
0.1% LFB overnight at 60 °C. Sections were then incubated 5 min in 0.05% lithium
carbonate before receiving the ethanol series and xylene. Bright field microcopy of
nerves at ×63 was used for quantification. Positive myelin staining is expressed as a
percentage of the total area examined.
Imaging. We used Olympus, BX51 with the following objectives: ×20, ×40, and ×63
equipped with the following cameras: Leica CCD Microscope DFC3000 G and
DMC2900 to obtain 16-bit light and fluorescence images (1296x966 pixels).
Fluorescence images were merged using Photoshop (Adobe) CS4 or NHI-Image J
software (US National Institutes of Health). We obtained confocal images using
Leica SP8 equipped with ×40 and ×64 objectives and super-sensitive HyD detec-
tors. We recorded each fluorescence signal as square 8-bit images (1024 × 1024
pixels). Images were postprocessed to generate maximal projections of Z-stacks
(acquired with a 0.4–0.8 µm step) and cross-sectional profiles of the Z-stack
(acquired with a 0.3 µm step) and pseudo-colored using Leica Application Suite X
(2.0.0.14332).
Quantification of MFI in tissue MNs. Fluorescence intensity levels of VPS35,
VPS26, CI-MPR, Sortilin, CTSD and Ubiquitin were calculated using NHI-Image J
software (US National Institutes of Health) according to the following protocol:
stacks of confocal images were used to generate the maximal projections using the
Leica Application Suite X (2.0.0.14332) software and then postprocessed by NHI-
Image J to crop single NeuN+ MNs from the ventral horn of the spinal cord. We
next performed background (calculated on adjacent slices only receiving secondary
antibodies) subtraction for each channel, before applying the NHI-Image J mean
filter (with radius 2.0 pixels) to calculate mean NeuN fluorescence levels in indi-
vidual MNs. Using this approach, we established a region of interest (ROI) to gate
single MNs. On this ROI, we measured mean fluoresce levels (MFI) of target
proteins.
Morphological assessment of Golgi apparatus in Neuro2a. Golgi morphology
was assessed in control or in Neuro2a cells receiving G93A plasmids with or
without compound 2a (10 µM) as well as in GFP-transfected cells as additional
control. We used Golgin97 immunofluorescence to label trans-Golgi network
membranes. We classified Golgi morphology as follow: normal (polarized net-
work), intermediate (partially fragmented) or fragmented (severely fragmented
with Golgi stacks dispersed in the cytoplasm throughout). In each experiment, cells
were randomly sampled across three coverslips. Golgi subclasses were expressed as
a percent of the total number of Golgi scored for each experimental condition.
Micro electrode array (MEA) recordings. Primary neuronal cultures were
established from the cerebral cortex of E16.5 C57BL6J embryos. Upon dissection,
cells were plated on MEA biochips (60 electrode MEA biochips with 200 µm
electrode spacing and 30 µm electrodes diameter with an integrated reference
electrode, Multichannel Systems GmbH) at the density of 3 × 105 cells/MEA and
kept in Neurobasal medium supplemented with B27 for 14 days. At day 14 neu-
ronal cultures were exposed to increasing concentration of compound 2a (1, 3, 10,
30, and 100 µM) in Krebs–Ringer–Hepes buffer (KRH, 130 mM NaCl, 5 mM KCl,
1.2 mM KH2PO4, 1.2 mM MgSO4, 2 mM CaCl2, 25 mM Hepes, 0.6% glucose, 1%
glutamine, Sigma–Aldrich). Firing activity was recorded using a pre-amplifier stage
(MEA-1060-Inv-BC-Standard, gain: 55, bandwidth: 300 Hz–8 kHz, MCS GmbH),
an amplification and filtering stage (FA64S, gain 20, bandwidth: 10 Hz–8 kHz,
MCS GmbH) and a data acquisition device (sampling frequency: 25 kHz). Then,
off-line signal processing was performed, and raw data were analyzed by MC-Rack
Software version 4.6.2 (MCS GmbH).
Real-time PCR. Lumbar spinal tracts dissected from saline-perfused mice or
Neuro2A cells were lysed to extract total RNAs using the RNeasy Mini Kit (Qia-
gen) according to the manufacturer’s recommendations, including DNase (Pro-
mega) digestion. We synthetized the cDNA using ThermoScript RT-PCR System
(Invitrogen) and Random Hexamer (Invitrogen), according to the manufacturer’s
instructions. The LightCycler 480 System (Roche) and LightCycler 480 SYBR
Green I Master Mix (Roche) were used for real-time PCR experiments. Normal-
ization was obtained using the housekeeping gene Histone H3:
F: 5′-GGTGAAGAAACCTCATCGTTACAGGCCTGGTAC-3′
R: 5′-CTGCAAAGCACCAATAGCTGCACTCTGGAAGC-3′
The following specific primers were used for gene expression analysis: VPS35F:
5′-GTGCCGTGGTGTGCAGCATCCG-3′VPS35R: 5′-ATGCTGCATCCGCACCC
AGAGC-3′VPS26A F: 5′-GCTAAGTATGAAATAATGGATGGGGC-3′VPS26A R:
5′-CTTGTTCACATCTCTCATCGTGGGG-3′VPS29F: 5′-CCAGCACATCCTCTG
CACCGGC-3′VPS29R: 5′-CCACGGAATAACTTGGTGTCCGTG-3′.
Statistics. We express data as the mean value (±standard error of the mean (SEM)
or ±standard deviation (SD)) of independent experiments. We assessed normality
of data applying either Kolmogorov–Smirnov test (with Dallas–Wilkinson–Lille for
P-value) or D'Agostino & Pearson omnibus normality test. Comparisons were
made using the following tests: unpaired t-test, one-way or two-way analysis of
variance (ANOVA) tests, followed by Tukey's multiple Comparison test or by
Bonferroni multiple comparison test. Statistical analyses were performed using
PRISM5.01, PRISM8.4.2 (GraphPad Software, La Jolla, CA, USA) or BioVinci 1.1.5
(BioTuring Inc.). Values lower than 0.05 were considered statistically significant.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Authors can confirm that all relevant data are included in the paper and its
supplementary information. Source data are provided with this paper. The data that
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